Compare PSN & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSN | BMRN |
|---|---|---|
| Founded | 1944 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 10.0B |
| IPO Year | 2019 | 1999 |
| Metric | PSN | BMRN |
|---|---|---|
| Price | $67.71 | $59.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 16 |
| Target Price | $84.00 | ★ $87.94 |
| AVG Volume (30 Days) | 1.3M | ★ 2.2M |
| Earning Date | 05-13-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.77 | N/A |
| EPS | ★ 2.20 | 1.80 |
| Revenue | ★ $6,364,245,000.00 | $1,313,646,000.00 |
| Revenue This Year | $6.45 | $11.04 |
| Revenue Next Year | $7.69 | $9.25 |
| P/E Ratio | ★ $29.78 | $34.29 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $54.56 | $50.76 |
| 52 Week High | $89.50 | $73.51 |
| Indicator | PSN | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 51.40 |
| Support Level | $66.62 | $56.08 |
| Resistance Level | $70.39 | $60.52 |
| Average True Range (ATR) | 2.32 | 2.62 |
| MACD | 0.33 | -0.09 |
| Stochastic Oscillator | 75.47 | 28.57 |
Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.